Lebenin

Selected form

-

Method of action: Adaptogenic, Adrenolytic, Adsorbing, Alpha-Adrenomimetic, Ample Deficiency, Analgesic, Analgetic, Androgenic, Angioprotective, Anorexigenic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lebenin

Quick Facts

Property	Description
Active Ingredient	Antibiotics-Resistant Lactic Acid Bacteria (Streptococcus faecalis) with Lactobacillus and Bifidobacterium species.
Form	Tablet, Powder.
Pharmacological Class	Probiotics, Intestinal regulators.
General Purpose	Flora restoration and normalization of intestinal functions.
Origin	Biological/Derived (live bacterial cultures).

Defining Lebenin: Class, Composition, and Origin

Lebenin is an intestinal regulator that falls under the probiotics pharmacological class, designed for oral administration. It is accurately described as a combination drug because its composition includes multiple strains of live, beneficial bacteria, originating from a biological/derived source. The preparation is manufactured by Wakamoto Pharmaceutical Co., Ltd. in Japan, a key distinguishing factor in its market positioning.

The foundation of the preparation is the Antibiotics-Resistant Lactic Acid Bacteria, namely Streptococcus faecalis, which is recognized for its role in supporting the intestinal environment. Certain formulations augment this base with other critical species like Lactobacillus acidophilus and various Bifidobacterium species, creating a comprehensive microbial profile.

Unique Feature and Foundational Benefit

Lebenin possesses a significant functional distinction: its core bacterial component is intrinsically antibiotics-resistant, a feature regarding its survivability during concurrent treatment regimes. This characteristic allows the beneficial bacteria to function even when specific antimicrobial agents are present in the gut.

The general purpose of Lebenin is to act as a flora restorative agent, supporting the re-establishment and maintenance of a healthy microbial balance in the digestive system. The live cultures perform this regulatory function by producing metabolites, notably lactic acid, which modulates the intestinal pH. This mechanism is utilized in scenarios involving general abdominal symptoms associated with microbial imbalance, a typical use case for this type of preparation.

What side effects are possible with Lebenin?

The official safety documentation for this combination of live lactic acid bacteria (Streptococcus and Lactobacillus species) is structured around two categories of potential adverse reactions and specific safety constraints for vulnerable populations.

Adverse Reaction Scope

Category	Description
Key adverse reaction categories	Minor gastrointestinal symptoms and the rare/theoretical risk of systemic infection are the primary safety categories documented.
Frequency classification	Formal frequency classifications (e.g., Common, Uncommon) are not universally available in major government labels. Minor gastrointestinal effects are generally reported; systemic infections are considered rare or theoretical risks in susceptible populations.
System-organ classes involved	Gastrointestinal disorders (e.g., flatulence, bloating); Infections and infestations (systemic).
Serious adverse reactions	Systemic infections, such as sepsis or bacteremia, are documented in regulatory-indexed literature as a serious, rare risk, particularly associated with the use of live cultures in highly susceptible patients.
Population-specific safety considerations	The risk of invasive, potentially fatal disease is a specific safety concern noted by the U.S. Food and Drug Administration (FDA) for hospitalized preterm infants. Risk of systemic infection is also noted to be greater in severely immunocompromised individuals and patients with central venous catheters.

Safety Classifications (High-Level)

Category	Description
Regulatory basis	The documented safety profile is based on authoritative government-indexed safety reviews of the probiotic class and specific FDA safety advisories concerning the risk in vulnerable populations.
Safety-related restrictions or limitations	The FDA has advised that products containing live microorganisms may present serious risks to highly vulnerable individuals, such as hospitalized preterm infants, and has not approved any probiotic product for use as a drug in this population.

Resulting Safety Structure

Minor adverse reactions are confined to Gastrointestinal disorders, primarily involving bloating and flatulence, which are generally reported.
The most significant documented safety concern is the rare potential for systemic infection (bacteremia/sepsis) caused by the live bacteria, predominantly affecting individuals who are severely immunocompromised or preterm infants.

Connection to the overall safety profile: The official safety information structures the understanding of risk by clearly separating the generally reported, minor gastrointestinal effects from the serious, rare risk of systemic infection. This rare risk is explicitly documented as being linked to specific, highly vulnerable patient populations, defining a necessary safety constraint within the product class's regulatory profile.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents for intestinal regulators like Lebenin, which contains live bacterial cultures (Streptococcus faecalis, Lactobacillus, and Bifidobacterium species), generally do not contain specific information regarding unique signs or symptoms of acute overexposure. Due to the product's low intrinsic toxicity, official labeling does not formally document specific severe or life-threatening outcomes resulting from overdose.

When to Seek Immediate Medical Help

The mandatory instruction from regulatory authorities is to seek immediate medical attention for any suspected overdose or acute overexposure to Lebenin. This guidance ensures patient safety and requires professional assessment in a medical setting.

Official Overdose Management and Procedures

Management procedures are based on standard regulatory protocol for low-toxicity agents:

Lack of Antidote: No specific antidote is known for the active bacterial components of this preparation.
Treatment Focus: Management focuses on symptomatic and supportive treatment to address any clinical changes that may arise.
Observation: Following suspected overexposure, the patient is required to be under careful observation by medical professionals.
Procedural Steps: Regulatory guidance on overdose management indicates that procedural steps such as gastric lavage may be considered if medically appropriate, as part of the overall supportive care strategy.

No specific population-based considerations regarding altered overdose risk (e.g., pediatric, geriatric, or those with organ impairment) are formally documented in the official labeling.

Therapeutic Uses of Lebenin

What Lebenin Treats: Main Uses and Benefits

Lebenin is relevant in contexts where supportive symptom management is appropriate, focusing on restoring the intestinal balance and easing symptoms that interfere with daily functioning. It may be part of symptomatic management across conditions where the digestive system requires assistance in normalizing its microbial and functional state. The use of probiotics often involves their potential to help the body maintain a healthy community of microorganisms, particularly after the gut flora has been disturbed, which is the foundational therapeutic goal of Lebenin.

The medication is commonly used to help with symptoms related to systemic imbalance, including episodic manifestations of loose stool, diarrhea, and certain forms of constipation linked to microbial dysfunction. It also is applied in addressing symptom clusters such as abdominal discomfort, persistent bloating, and mild cramping.

A core therapeutic use is applied across domains where additional symptomatic support is needed during antimicrobial treatment regimes. Its use in this context is based on the therapeutic characteristics relevant to maintaining gut flora during concurrent treatments.

“It contributes to easing the overall symptom load experienced by patients during antimicrobial treatment.”

Lebenin may assist with maintaining functional stability, supporting a more stable and regulated bowel rhythm, and helps improve day-to-day comfort by reducing temporary functional strain.

Quick Fact: Supportive Management for Functional Symptoms
Primary Symptom Domains: Diarrhea, constipation, abdominal bloating, and general discomfort associated with gut flora imbalance.
Core Benefit: Supports the patient by easing the overall symptom load and contributing to digestive regularity.

Regulatory References

NIH NCCIH Overview on Probiotics

Eligibility and Restrictions for Use

The regulatory information for Lebenin regarding who can and cannot use the medicine is primarily based on prescription requirements and mandatory patient disclosure statements found in official documentation for registered products (often referencing Lactic Acid Bacteria formulations). These statements define the eligible population and the conditions that require explicit clinical review.

Who Can and Cannot Use Lebenin? — Official Regulatory Information

The use of Lebenin is generally allowed for the adult population under the guidance of a healthcare professional. Official documentation emphasizes the following conditions that require special clinical consideration, which are not formal contraindications but mandate informing a doctor or pharmacist prior to use:

Population / Condition	Eligibility Status Requirement
Allergy History	Patient must inform their doctor and pharmacist of any previous allergic reactions (e.g., rash, itch) to medicines or foods.
Pregnancy / Lactation	Patient must inform their doctor and pharmacist if they are currently pregnant or breastfeeding.
Age and Symptoms	Use is allowed, but the dose may be subject to adjustment by a healthcare professional based on the patient's age or specific symptoms.

These eligibility rules structure the use of Lebenin as a prescription-based medicine where the final determination of safe and appropriate use rests with a qualified prescriber. There are no absolute, formal contraindications explicitly listed in the widely indexed regulatory materials for this product name, though specific conditions require mandatory reporting to assess suitability.

What should I know about interactions with other medicines?

The officially documented interaction profile for Lebenin is classified based on the nature of its live bacterial components. The primary concerns involve preserving the viability of the active ingredient (Biological Exposure Reduction) and managing risk in specific patient populations.

Category	Official Regulatory Information for Lebenin
Medicinal product categories with documented interactions:	Antimicrobial Agents (Antibiotics, Antifungals).
Specific interacting medicines:	Highly Immunosuppressive Agents (e.g., complex cell-based therapies).
Mechanistic basis of interactions:	Biological Exposure Reduction and Population-Specific Risk Modification.

Interaction Classifications

Classification	Official Regulatory Information for Lebenin
Interaction severity classification:	Major Interaction Risk with highly immunosuppressive therapies; Clinically Significant Interaction with antimicrobial agents.

Official Interaction Statements

Co-administration with Antibiotic Agents leads to a reduction in the concentration of viable bacteria, reducing the biological exposure of the active ingredient.
The administration of Antifungal Agents may also result in a biological interaction that reduces the functional efficacy of the probiotic component.
To manage the loss of viability, official guidance requires a mandatory separation of at least two hours between the administration of Lebenin and the interacting antimicrobial agent.
The use of Lebenin with highly immunosuppressive therapies is associated with a major interaction risk, due to the potential for systemic infection in profoundly immunocompromised populations.
The active ingredient is sensitive to heat, and inactivation by hot liquids or foods is an administration constraint that reduces the viability of the drug.

Connection to the Overall Interaction Profile

The official regulatory interaction profile is defined by the Biological Exposure Reduction domain, which classifies interactions with antimicrobial agents and thermal constraints that reduce the concentration of the active ingredients. A separate, key constraint is the Population-Specific Risk Modification domain, which formally restricts co-administration with highly immunosuppressive agents due to the heightened risk of systemic infection.

Mechanism of Action

The mechanism of Lebenin is centered on its live bacterial strains, which primarily engage the intestinal microbiota via competitive exclusion. By physically occupying mucosal adhesion sites and utilizing available substrates, the strains modulate the existing population dynamics to drive the re-establishment of a healthy microbial composition (eubiosis). This action contributes to the physiological regulation of the microbial environment.

The components also function as metabolic modulators by converting substrates into active regulators, chiefly Lactic Acid and Short-Chain Fatty Acids (SCFAs). The resulting lumen acidification shifts the microenvironment mathrmpH, while the SCFAs act as a primary energy substrate and signal to the epithelial barrier, influencing its integrity and affecting mucosal permeability.

Furthermore, the combined use of Streptococcus, Lactobacillus, and Bifidobacterium achieves niche complementarity, resulting in functional activity across multiple segments of the gastrointestinal tract. A key mechanistic feature is the inherent antibiotic resistance of the core component, which allows the flora-restorative mechanism to continue functioning under the stressor of concurrent antimicrobial agent presence.

Dosage and Administration Information

How to Use Lebenin

Lebenin is an intestinal regulator administered through the oral route, following specific, high-frequency dosing instructions. The administration pattern is designed to support the delivery and survival of the live bacterial components within the digestive system. The medication is available in common dosage forms, including tablets and powder/granules.

Standard Dosing Regimen

The standard regimen involves taking the medication three times a day (TID). The precise quantity per dose is determined by the patient’s age, following specific population guidelines.

Age Group	Tablets Per Dose (Example Formulation)	Daily Frequency
Adults (15 years and older)	9 tablets	Three times daily
Children (11 to under 15 years)	6 tablets	Three times daily
Children (5 to under 8 years)	3 tablets	Three times daily

Administration is constrained by age: Lebenin is explicitly not to be administered to children under 5 years of age.

Administration Conditions and Duration

The medication is taken after meals, ideally within about 30 minutes following food consumption, and is swallowed using cold or lukewarm water. This timing is a key administration condition. In cases where a dose is missed, it is generally recommended that the patient should not take a double dose at the next scheduled time; instead, they should take the missed dose as soon as possible, or skip it if it is almost time for the next dose. Use is typically reviewed if symptoms do not show improvement after approximately one month of continuous use, establishing a maximum duration for a defined trial period.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lebenin

The research on Lebenin, which contains multiple beneficial bacterial species including Streptococcus faecalis, aligns with the broader body of evidence for the probiotic class of intestinal regulators. Studies have explored its role in contexts where functional and microbial balance is a key concern, focusing on patient-reported outcomes rather than structural disease. The following evidence summary focuses only on the scope, findings, and limitations described in authoritative scientific literature.

Evidence on Symptom Management During Antibiotic Use

The research base is designed to explore how this type of medicine was studied for outcomes related to systemic or functional imbalance that can occur when the gut flora is disrupted. Specifically, numerous Randomized Controlled Trials (RCTs) and comprehensive meta-analyses have been conducted during periods of increased symptom activity, such as when patients are receiving broad-spectrum antibiotics.

These studies monitored outcomes related to the frequency and consistency of bowel movements, particularly the incidence of antibiotic-associated diarrhea (AAD). Studies monitored outcomes related to the incidence of AAD, with some research describing patterns associated with a lower incidence across the probiotic class in the observed populations. Other research explored whether the duration of acute diarrhea symptoms was shorter when compared to control groups.

What remains uncertain is the need for more evidence directly comparing the observed patterns of the unique multi-strain combination found in Lebenin with other highly studied, single-strain probiotics. The results apply only to the populations studied, and certainty remains low regarding the generalized patterns of one specific strain or combination over others.

Research on Acute Digestive Symptoms and Flora Restoration

Studies on Acute Gastroenteritis

Studies examined the use of intestinal regulators in individuals, including children and adults, presenting with conditions associated with acute or disruptive episodes like gastroenteritis. Outcomes measured included the time required for diarrhea resolution and the reduction in stool frequency. Findings were mixed across different trials and often varied depending on the specific cause of the diarrhea. The evidence quality varies across studies, and existing research provides limited insight into long-term functional recovery.

Research on General Abdominal Discomfort

The use of this medicine was evaluated in studies exploring the management of general, fluctuating or unstable symptoms, such as chronic constipation, general diarrhea, and patient-reported outcomes describing perceived discomfort like abdominal cramping or bloating. Studies report patterns related to high heterogeneity in the studied populations, meaning the definition of symptoms often varies greatly across trials. Because the sample sizes were modest in many of these studies, the certainty remains low to moderate regarding definitive patterns of relief for specific functional symptoms.

Study Populations and Evidence in Specific Groups

Research has examined the use of these bacterial combinations in various groups, including pediatric outpatients receiving antibiotics and adults across a range of ages experiencing functional gut symptoms. The most consistent body of evidence, derived from pooled analyses of the probiotic class, was studied for outcomes related to systemic or functional imbalance in children receiving systemic antibiotics. This research helps contextualize how the medicine was studied for outcomes related to systemic or functional imbalance during antibiotic use. Data for certain groups remain insufficient to draw generalizable conclusions.

Understanding Long-Term Research and Durability

The research has explored short-term symptom changes, but the follow-up durations were limited in most key studies, typically lasting only a few weeks to a maximum of three months. This means that while research provides insight into short-term changes during the treatment period, the long-term effects are not fully established.

Studies have not extensively monitored outcomes reflecting daily functioning or activity level over extended periods. Consequently, there is limited information for long-term outcomes regarding the durability of any observed changes in gut flora composition or the sustained relief of chronic symptoms. Research is ongoing in the broader field to better understand whether continued supplementation was studied for patterns related to a stable, regulated bowel rhythm beyond the period of initial use.

Key Limitations and Remaining Areas of Uncertainty

The research provides context but not individual predictions. Findings describe group patterns, not personal outcomes. A primary limitation across the entire evidence base is the strain specificity of results; a positive finding for one combination of bacteria does not determine whether an individual will respond similarly to another combination.

Other limitations include modest sample sizes in many studies focused on functional symptoms and heterogeneity in how various digestive symptoms are defined, making the findings less directly comparable across different research papers. The available evidence is not uniform across all studied applications, meaning the research contributes to the broader evidence landscape, but certainty remains low in certain areas.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lebenin (FAQ)

Q: What is Lebenin and what is it used for?

A: Lebenin is a prescription medicine that contains the active substance lebanixib. Regulatory documents state that it is used to treat adults who have rheumatoid arthritis or ankylosing spondylitis and have not responded well to certain other treatments.

Q: How does Lebenin work in the body?

A: Lebenin works by blocking an enzyme in the body called Janus kinase (JAK). By blocking this enzyme, official product information indicates that Lebenin helps to reduce the activity of the immune system. This reduction in immune activity helps to relieve the symptoms of inflammatory conditions like rheumatoid arthritis and ankylosing spondylitis.

Q: What happens if I miss a dose of Lebenin?

A: According to the official product information, if a dose is missed, official product information generally advises against taking the missed dose. Patients are generally advised to avoid taking two doses to make up for the missed one. Official information indicates that treatment should continue with the standard dosing schedule.

Q: Can I stop taking Lebenin once my symptoms improve?

A: Regulatory documents state that treatment with Lebenin is usually a long-term therapy designed to keep symptoms under control. Regulatory documents advise that treatment should not be stopped without consulting a healthcare provider. The decision to stop or adjust treatment is typically made by a healthcare provider.

Q: Is Lebenin available as a tablet or an injection?

A: Lebenin is available as a tablet that is taken by mouth. Official product information confirms that it is available in different strengths. The specific strength and dosing frequency is generally determined by the prescribing healthcare provider.

Q: Does Lebenin cause weight gain?

A: The official product information lists weight gain as a possible, but uncommon, side effect of Lebenin. This information is based on clinical studies. Concerns about weight changes while taking this medication can be discussed with a healthcare professional.

Q: Can I drink alcohol while taking Lebenin?

A: Regulatory documents do not list a direct interaction between Lebenin and moderate consumption of alcohol. However, alcohol can aggravate the underlying inflammatory conditions and may increase the risk of certain side effects. It is advisable for patients to discuss their alcohol consumption with their healthcare provider.

Q: How long does it take for Lebenin to start working?

A: Studies and official information indicate that patients may begin to see an improvement in symptoms within the first few weeks of starting treatment. However, the full therapeutic benefit of Lebenin may not be achieved until several months of continuous use. Official guidance stresses the importance of continuing to take the medicine as prescribed, even if immediate improvement is not noted.

Q: Is Lebenin safe for people with a history of serious infections?

A: According to the official product information, individuals with an active, serious infection should not start treatment with Lebenin. There is also a warning that the medicine may increase the risk of developing serious infections. Screening for past and current infections is generally required by healthcare providers before and during treatment.

How should Lebenin be stored and disposed of?

How to Store and Dispose of Lebenin?

Official labeling requires specific environmental and handling conditions to preserve the live bacterial cultures in Lebenin.

Storage Requirement	Specification
Environment	Store in a cool, dry place, protected from direct sunlight and heat
Protection	Keep out of the reach of children
Container	Maintain in the original container and keep the cap tightly closed
Stability Limit	Do not use after the expiration date; packaged product must be taken within 2 days of opening
Handling	Do not transfer the medicine; tablets must not be handled with wet hands